Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(33%)
Results Posted
200%(2 trials)
Terminated
1(33%)

Phase Distribution

Ph not_applicable
3
100%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
N/ANon-phased studies
3(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)

Detailed Status

Completed1
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
50.0%
Most Advanced
N/A

Trials by Phase

N/A3 (100.0%)

Trials by Status

completed133%
active_not_recruiting133%
terminated133%

Recent Activity

1 active trials
Showing 3 of 3
active_not_recruitingnot_applicable

Partial Breast Proton Therapy for Early Stage Breast Cancer

NCT01310530
completednot_applicable

Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma

NCT00857805
terminatednot_applicable

Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria

NCT01141478

Clinical Trials (3)

Showing 3 of 3 trials
NCT01310530Not Applicable

Partial Breast Proton Therapy for Early Stage Breast Cancer

Active Not Recruiting
NCT00857805Not Applicable

Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma

Completed
NCT01141478Not Applicable

Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria

Terminated

All 3 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
3